MYDGF (D17Wsu104e)
(DNA segment, Chr 17, Wayne State University 104, expressed (D17Wsu104e))
Protein-Typ
Recombinant
Spezies
Human
Quelle
Escherichia coli (E. coli)
Aufreinigungstag / Konjugat
Dieses MYDGF Protein ist gelabelt mit His tag.
Verwendungszweck
Recombinant Human Myeloid-derived Growth Factor is produced by our E.coli expression system and the target gene encoding Ser33-Leu173 is expressed with a 6His tag at the N-terminus.
Produktmerkmale
Extracellular Domain Protein
Aufreinigung
Affinity purification
Reinheit
Greater than 95 % as determined by reducing SDS-PAGE.
D17Wsu104e
Spezies: Human
Wirt: Escherichia coli (E. coli)
Recombinant
> 95 % by SDS - PAGE
SDS
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Buffer
Lyophilized from a 0.2 μm filtered solution of 4 mM HCl.
Lagerung
-20 °C,-80 °C
Informationen zur Lagerung
Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Haltbarkeit
12 months
Target
MYDGF (D17Wsu104e)
(DNA segment, Chr 17, Wayne State University 104, expressed (D17Wsu104e))
Myeloid-derived growth factor (MYDGF) is a secreted protein which belongs to the UPF0556 family. MYDGF was strongly expressed in spleen, prostate and lung, and weakly expressed in the left ventricle and liver. Bone marrow-derived monocyte and paracrine-acting protein promotes cardiac myocyte survival and adaptive angiogenesis for cardiac protection and/or repair after myocardial infarction (MI). MYDGF stimulates endothelial cell proliferation through a MAPK1/3-, STAT3- and CCND1-mediated signaling pathway. It inhibits cardiac myocyte apoptosis in a PI3K/AKT-dependent signaling pathway. MYDGF is involved in endothelial cell proliferation and angiogenesis. It may serve as a prototypical example for the development of protein-based therapies for ischemic tissue repair.